Left Ventricular Dysfunction
95
12
20
50
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Published Results
14 trials with published results (15%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
5.3%
5 terminated out of 95 trials
90.9%
+4.4% vs benchmark
13%
12 trials in Phase 3/4
28%
14 of 50 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 50 completed trials
Clinical Trials (95)
Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function
The JenaValve ALIGN-AR LVAD Registry
PASCAL Precision-GDMT Registry
IMpella-Protected cArdiaC Surgery Trial (IMPACT)
UC-MSC Transplantation for Left Ventricular Dysfunction After AMI
Menopausal Hormone Therapy And Left Ventricular Function
Risk Stratification of Cancer Therapy-Related Cardiac Dysfunction Using AI-Enhanced Electrocardiography
AI-ECG for Time-Resolved Prediction of HFrEF
London Valvular Heart Disease and Reduced Ejection Fraction Detection in a Multi-ethnic Community Using Cardiac Ultrasound
DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction
Assement of Left Ventricular Function Before Decannulation in Cardiac Surgery :Visual Estimation vs TEE
Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)
Myocardial Protection in Patients With Post-acute Inflammatory Cardiac Involvement Due to COVID-19
PRE-DETERMINE Cohort Study
IMPACT EU Post-Market Clinical Follow-Up Study
Evaluation of the BIOTRONIK AutoAdapt Algorithm for Continuous Automatic Adaptive Cardiac Resynchronization
Prevalence and Risk Factors asSOciated With CArdiac comorbiDIty in psoriAsis
Conventional Biventricular Versus Left Bundle Branch Pacing on Outcomes in Heart Failure Patients
HIDRAdenitis Suppurativa and HEART Disease
Cardiac Structure and Function in Patients with Cystic Fibrosis